Metabolic dysregulation in the Atp7b−/− Wilson’s disease mouse model

Clavia Ruth Wooten-Kee1, Matthew Robertson2, Ying Zhou3, Bingbing Dong4, Zhen Sun5, Kang Ho Kim6, Hailan Liu6, Yong Xu6, Nagireddy Puturi7, Pradip Saha5, Cristian Coarfa5, David D. Moore6,7,8,9, and Alli M. Nuotio-Antar7,1

1Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030; 2Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030; 3Integrative Molecular and Biomedical Sciences Graduate Program, Baylor College of Medicine, Houston, TX 77030; and 4Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030

Contributed by David D. Moore, December 8, 2019 (sent for review August 18, 2019; reviewed by Ronald M. Evans and Mitchell A. Lazar)

Inactivating mutations in the copper transporter Atp7b result in Wilson’s disease. The Atp7b−/− mouse develops hallmarks of Wilson’s disease. The activity of several nuclear receptors decreased in Atp7b−/− mice, and nuclear receptors are critical for maintaining metabolic homeostasis. Therefore, we anticipated that Atp7b−/− mice would exhibit altered progression of diet-induced obesity, fatty liver, and insulin resistance. Following 10 wk on a chow or Western-type diet (40% kcal fat), parameters of glucose and lipid homeostasis were measured. Hepatic metabolites were measured by liquid chromatography–mass spectrometry and correlated with transcriptional data. Atp7b−/− mice fed a chow diet presented with blunted body-weight gain over time, had lower fat mass, and were more glucose tolerant than wild type (WT) littermate controls. On the Western diet, Atp7b−/− mice exhibited reduced body weight, adiposity, and hepatic steatosis compared with WT controls. Atp7b−/− mice fed either diet were more insulin sensitive than WT controls; however, fasted Atp7b−/− mice exhibited hypoglycemia after administration of insulin due to an impaired glucose counterregulatory response, as evidenced by reduced hepatic glucose production. Coupling gene expression with metabolomic analyses, we observed striking changes in hepatic metabolic profiles in Atp7b−/− mice, including increases in glycolytic intermediates and components of the tricarboxylic acid cycle. In addition, the active phosphorylated form of AMP kinase was significantly increased in Atp7b−/− mice relative to WT controls. Alterations in hepatic metabolic profiles and nuclear receptor signaling were associated with improved glucose tolerance and insulin sensitivity as well as with impaired fasting glucose production in Atp7b−/− mice.

nuclear receptors | liver | copper

Wilson’s disease is an autosomal recessive disorder with equal prevalence in males and females caused by mutations in the copper transporter Atp7b. The result is free copper concentrations that exceed the functional capacity of copper-binding proteins, causing oxidative stress, hepatic inflammation, steatosis, fibrosis, and cirrhosis (1). The variable clinical presentation of metabolic disorders in Wilson’s disease patients has been attributed to differing environmental and genetic factors (2). Recent metabolomic analysis of serum from Wilson’s disease patients identified unique signatures including enrichment in the tricarboxylic acid cycle, amino acid metabolism, choline metabolism, and oxidative stress pathways (3). In agreement with these findings, a Wilson’s disease rat model of chronic copper feeding had alterations in serum metabolite profiles, including decreased serum glucose (4).

Nuclear receptors play a central role in the regulation of hepatic metabolism. Defects in nuclear receptor signaling and lipid metabolism have been identified in patients with Wilson’s disease and in Atp7b−/− mice (5–7). In accord with this, we found that activity of the nuclear receptors FXR, RXRα, HNF4α, and LHRH1 decreased in livers of Atp7b−/− mice (8). Additional results in humans [PPARα (9, 10)] and mice [FXR (7, 8), LXR (5)] link metabolic and nuclear receptor dysfunction to Wilson’s disease. Whole-genome sequencing revealed differentially methylated regions for genes involved in lipid metabolism, including HNF4α and RXR α targets, in Wilson’s disease patients (11).

We sought to further define metabolic consequences of Wilson’s disease, hypothesizing that Atp7b−/− mice would exhibit an altered metabolic phenotype linked to changes in nuclear receptor signaling. Here, we describe an unexpected increase in whole-body glucose tolerance and insulin sensitivity coupled with decreased fasting glucose production in Atp7b−/− mice. Metabolomic and transcriptomic profiles link these findings with alterations in nuclear receptor target gene expression.

Results

Atp7b−/− Mice Are Protected from Diet-Induced Obesity. In accord with expectations from Wilson’s disease and previous reports (8), Atp7b−/− mice on a C57BL/6J background showed elevated hepatic copper, but not iron, levels, which were associated with induction of metallothionein 2 (Mt2) expression (SI Appendix, Fig. S1 A and B). At the end of the study, Atp7b−/− mice had elevated serum ALT, ALP, and bilirubin (total, direct, and indirect), and lower albumin; however, globulin level and the albumin/globulin ratio were unchanged, suggesting that liver function was not significantly impaired (SI Appendix, Fig. S1 C–H).

Significance

Wilson’s disease is an autosomal recessive disorder that results in accumulation of toxic levels of copper in the liver, which can lead to cirrhosis and liver failure. Emerging evidence suggests that hepatic metabolic processes are altered in Wilson’s disease patients and Wilson’s disease animal models. Our studies revealed an unexpected improvement in glucose tolerance and insulin sensitivity in a Wilson’s disease mouse model (Atp7b−/−) that correlate with activation of AMPK. These findings have the potential to uncover therapeutic options for patients with Wilson’s disease, as well as for patients with metabolic disorders such as type 2 diabetes and fatty liver disease.


Reviewers: R.M.E., Salk Institute for Biological Studies; and M.A.L., University of Pennsylvania.

The authors declare no competing interest.

Published under the PNAS license.

Data deposition: The data reported in this paper have been deposited in the Gene Expression Omnibus database, https://www.ncbi.nlm.nih.gov/geo/ (accession no. GSE125637).

1To whom correspondence may be addressed. Email: wootenke@bcm.edu, moore@bcm.edu, or antar@bcm.edu.

This article contains supporting information online at https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1914267117/-/DCSupplemental.

to Atp7b<sup>−/−</sup> mice on a mixed genetic background, Atp7b<sup>−/−</sup> mice had pleomorphic nuclei, ballooned hepatocytes, and microsteatosis; however, significant inflammation was not apparent (SI Appendix, Fig. S2) (12).

There are conflicting reports of metabolic status in Wilson’s disease patients (13, 14). We assessed differences in body weight and composition, as well as the response of Atp7b<sup>−/−</sup> mice to a Western-type diet challenge. For metabolic phenotyping experiments, we chose to study male mice since female C57BL/6J mice have been reported to be protected from obesity and insulin resistance in comparison to males (15). Starting at 6 wk of age, Atp7b<sup>−/−</sup> and wild-type (WT) mice were provided a normal chow or a high-fat, high-sucrose Western-type diet and weighed for 10 wk prior to metabolic phenotyping experiments. Body-weight gain over time, total fat mass, and epididymal white adipose tissue (eWAT) weight were moderately decreased in chow-fed Atp7b<sup>−/−</sup> mice in comparison with WT littermate controls (Fig. 1A). On a Western diet (WD), body-weight gain was more blunted and endpoint total fat mass and liver and eWAT weights were reduced in Atp7b<sup>−/−</sup> mice compared with WT mice (Fig. 1A). Lean body mass and kidney weight, representative of lean mass, did not differ between genotypes on either chow or WD (SI Appendix, Figs. S3A and B).

The decreased adiposity exhibited by Atp7b<sup>−/−</sup> mice suggested differences in energy balance between Atp7b<sup>−/−</sup> and WT mice. Therefore, indirect calorimetry was performed simultaneously with measurement of activity and food intake at a time point prior to significant differences in body weight. Total daily food consumption decreased for chow-diet–fed Atp7b<sup>−/−</sup> mice compared with littermate WT controls due to decreased food consumption during the dark (active) cycle (SI Appendix, Fig. S4A and B). Although respiratory exchange ratio (RER) did not differ during the light (inactive) cycle, RER was increased during the dark cycle, indicating enhanced carbohydrate oxidation for Atp7b<sup>−/−</sup> mice vs. WT controls (SI Appendix, Fig. S4C). Both ambulatory x-axis (walking) and z-axis (rearing or jumping) activities increased, whereas total X-activity (walking and stereotypy) did not differ for Atp7b<sup>−/−</sup> mice compared with WT controls (SI Appendix, Figs. S4D–F and S5). Although locomotor activity profiles differed, VO<sub>2</sub> and energy expenditure (heat) did not differ between Atp7b<sup>−/−</sup> mice and WT littermate controls (SI Appendix, Figs. S4G and H). These results link the decreased body-weight gain of Atp7b<sup>−/−</sup> mice primarily to decreased food intake, with an additional potential contribution from increased activity.

**Decreased Hepatic Steatosis in Atp7b<sup>−/−</sup> Mice.** In accordance with previous reports (5, 6), parameters of lipid metabolism were altered in Atp7b<sup>−/−</sup> mice. WD-fed WT animals had increased serum and hepatic cholesterol (CHOL), triglycerides (TG), and free fatty acids (FFA) (Fig. 1B). However, WD-fed Atp7b<sup>−/−</sup> mice had decreased hepatic CHOL, TG, and FFA in comparison with WT.
mice (Fig. 1B). Consistent with quantitative assessment of hepatic lipid content, Oil Red O staining showed decreased neutral-lipid staining for both the chow-fed and the WD-fed Atp7b−/− mice relative to WT controls (SI Appendix, Fig. S6A). Oil Red O staining was also notable in nuclei of Atp7b−/− mice on both diets (SI Appendix, Fig. S6). Cd36 expression increased, suggesting that Atp7b−/− deficient hepatocytes take up more fatty acids (SI Appendix, Fig. S6B). However, in keeping with previous studies (7), both Acox1 and Mfp1 expression decreased, suggesting decreased beta oxidation, although Cpt1a expression was not different. Ucp2 expression increased in Atp7b−/− vs. WT control livers.

**Atp7b−/− Mice Are More Glucose Tolerant and Insulin Sensitive.** Glucose tolerance tests (GTT) revealed increased glucose tolerance in Atp7b−/− mice fed chow diet in comparison with WT mice (Fig. 2A). Although the GTT curves did not differ between WD-fed Atp7b−/− and WT mice, insulin levels in response to glucose injection decreased at all time points for WD-fed Atp7b−/− mice in comparison to WT mice, suggesting enhanced insulin sensitivity in both chow and WD-fed Atp7b−/− mice (Fig. 2B and C). Insulin tolerance tests (ITT) and homeostatic model assessment of insulin resistance (HOMA-IR) levels supported increased insulin sensitivity in both chow and WD-fed Atp7b−/− mice (Fig. 2D–F). In accord with this, hyperinsulinenic-euglycemic clamp studies showed increased glucose infusion rate and rate of disappearance of glucose (Rd) in Atp7b−/− mice (Fig. 2 G and H). This was accompanied by an increased metabolic index of glucose (Rg) (a marker of glucose uptake) in gastrocnemius muscle and eWAT in Atp7b−/− mice (Fig. 2I and J). The endogenous rate of appearance of glucose (Ra), an index of endogenous glucose production, was not different between groups prior to or post insulin infusion (Fig. 2K). Consistent with enhanced glucose uptake, increased AMPK activation was observed in gastrocnemius muscle of chow-diet-fed Atp7b−/− mice in comparison with WT controls (Fig. 2L).

Both chow- and WD-fed Atp7b−/− mice exhibited striking hypoglycemia following insulin administration after fasting, with blood glucose levels dipping below 80 mg/dL by 15 and 45 min, respectively, suggesting an impaired glucose counterregulatory response (Fig. 2D and E) (16). Pyruvate tolerance tests (PPT) also indicated that fasted-state gluconeogenesis in Atp7b−/− mice fed either chow or WD may be blunted relative to WT controls (Fig. 3A and B). Hepatic expression of glucose-6-phosphate dehydrogenase (G6pd) expression was significantly decreased in Atp7b−/− relative to WT mice (SI Appendix, Fig. S7A). Although initial UDP-glucose measurements did not differ between groups, quantitative (colorimetric enzyme assays) and qualitative [periodic acid–Schiff (PAS) staining] methods demonstrated decreased hepatic glycogen content in ad-libitum-fed Atp7b−/− vs. WT mice, reflecting a potential defect in synthesis and/or storage of glucose (SI Appendix, Fig. S7 B–D). In contrast with normal hepatocytes, hepatocytes with abnormal morphology (ballooning with pleiomorphic nuclei containing inclusions) were unstained by PAS in Atp7b−/− mice (SI Appendix, Fig. S7C). These results reveal that hepatic glycogen production in the fasted state and glycogen stores may be decreased in Atp7b−/− mice.

**Hepatic AMPK Activation in Atp7b−/− Mice.** AMPK is activated in response to diverse cellular stresses, including increased reactive oxygen species (ROS) production. The well-established connection between excess intracellular copper and redox stress in WD suggested that hepatic AMPK activation could play a role in the metabolic phenotypes observed in Atp7b−/− mice. Therefore, we measured total and phospho-AMPK in the liver. Chow-fed Atp7b−/− mice did indeed have increased hepatic p-AMPKα but not total AMPK, as shown by Western blot (Fig. 3C). In agreement with the expected impact of hepatic AMPK activation to decrease gluconeogenesis and lipogenesis, Ppck1, Pcx, Fbp1, Fasn, Acc1, and Srebplc expression levels were reduced in Atp7b−/− mice in comparison with WT controls (Fig. 3 D and E).

**Hepatic Metabolite Composition in Atp7b−/− Mice.** Analysis of the TCA cycle and glycolytic metabolic pathways revealed dramatic changes in hepatic metabolites. Atp7b−/− mice had decreased hepatic glucose, pyruvate, and lactate levels; however, several glycolytic intermediates increased (G6p/F6p, 2PG/3PG, and PEP) (Fig. 4A). Similarly, there was an accumulation of TCA intermediates (oxaloacetate, α-ketoglutarate, and fumarate), suggesting metabolic adaptation in the livers of Atp7b−/− mice. Cancer metabolism and integrated stress-response studies have described a role for Pepck2 (mitochondrial Pepck) in the promotion of catastrophic mechanisms that promote “pyruvate recycling” as a mechanism for cell adaptation in conditions of stress (17, 18). Despite decreased Pepck1, Pepck2 expression significantly increased in Atp7b−/− mice (Fig. 4B). While the mechanism(s) for increased Pepck2 in Atp7b−/− mice are presently unclear, it is possible that copper-induced cellular stress is driving activation of endoplasmic reticulum-stress–mediated pathways previously shown to increase Pepck2 (18).

In contrast, acetyl-CoA and α-KG decreased in Atp7b−/− mice (Fig. 4A), which was accompanied by an increase in pyruvate dehydrogenase kinase 4 (Pdk4) and a decrease in pyruvate dehydrogenase a1 (Pdhα1) expression (Fig. 4C). Pyruvate dehydrogenase inactivation is reversed via dephosphorylation by the pyruvate dehydrogenase phosphatase enzyme (19). Together with increased Pdk4 expression, the decreased Pdhα1 expression in Atp7b−/− mice (Fig. 4C) may limit pyruvate flux into the TCA cycle. Furthermore, the changes in TCA cycle intermediates coincided with decreased Mdh1 and succinate dehydrogenase complex (Sdhb) and increased Idh2 gene expression (Fig. 4D).

**Hepatic Transcriptomic Analysis and Predicted Transcription Factor Alterations in Atp7b−/− Mice.** Microarray transcriptomic analysis was performed with 3-mo-old WT and Atp7b−/− mice (SI Appendix, Figs. S8 and S9), an age at which nuclear receptor dysfunction was detectable but livers lacked significant pathology (8, 12, 20). Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis showed that up-regulated pathways included proteasome, cell cycle, protein catabolism, oxidative phosphorylation, detoxification (glutathione metabolism), and TCA cycle. Pathways involved in immunity, calcium signaling, and synthesis of unsaturated fatty acids were in down-regulated genes (Fig. S8A). These findings are in keeping with transcriptomic studies in younger Atp7b−/− mice on a mixed background and in Wilson’s disease patients (5, 6).

Furthermore, microarray data revealed significantly increased hepatic expression of the anorectic hepatokine Gdf15 (SI Appendix, Table S1). Real-time PCR confirmed a fourfold increase in hepatic Gdf15 expression for chow-diet–fed Atp7b−/− mice at both 3 and 6 mo of age (SI Appendix, Fig. S10A). Serum GDF15 was also increased fourfold for chow-fed Atp7b−/− mice at both 3 and 6 mo of age. Although Western diet feeding significantly increased serum GDF15 in WT mice, circulating GDF15 levels remained significantly greater in WD-fed Atp7b−/− mice in comparison with WT controls (SI Appendix, Fig. S10B).

Transcription-factor–binding sites enriched within the regulatory regions of significantly changed gene sets were identified using EnrichR Analysis. As expected, nuclear-receptor–binding elements were strongly associated with down-regulated genes. In agreement with previous reports (7, 20), RXRα- and LXRα–binding sites were the most highly enriched in down-regulated genes, likely reflecting dysfunctional nuclear receptor activity (Fig. 5). LXR-binding elements were also enriched to a lesser extent in the up-regulated gene dataset. PPARα elements, along with PXR (a xenobiotic detoxification nuclear receptor), were represented in the down-regulated gene data set. Transcriptomic analysis of decreased genes containing PXR-binding elements included Cyp7b1 and Elov2, revealing a link between aberrant xenobiotic and lipid metabolism and lipogenesis (SI Appendix, Table S1).
Fig. 2. Glucose tolerance and insulin sensitivity in Atp7b<sup>−/−</sup> mice. (A and B) GTT. (C) Insulin released during intraperitoneal (IP)-GTT time course. (D and E) ITT was performed on 6-mo-old Atp7b<sup>−/−</sup> and WT mice fed either (A and D) chow or (B and E) WD. (F) HOMA-IR. (G–K) Hyperinsulinemic euglycemic clamp was performed with 4- to 7-mo-old chow-fed Atp7b<sup>−/−</sup> and WT mice. (L) Western blot analysis of gastrocnemius muscle AMPK and p-AMPK levels in chow-fed WT and Atp7b<sup>−/−</sup> mice. (A–F) *p < 0.05, WT vs. Atp7b<sup>−/−</sup>, chow; #p < 0.05 WT vs. Atp7b<sup>−/−</sup>, WD; two-way ANOVA, and Sidak’s post hoc test. n = 4 to 11/group. (G–K) *p < 0.05, Student’s t test for Atp7b<sup>−/−</sup> mice vs. WT; n = 5 to 6 mice/group.
The most abundant transcription-factor–binding elements within the up-regulated genes were binding sites for FoxM1, E2F4, and androgen receptor (AR), which is consistent with cell-cycle pathway enrichment in the KEGG pathway analysis of the transcriptomic data (SI Appendix, Fig. S9B).

Discussion

Copper-mediated impairment of liver function is well characterized in Wilson’s disease patients and in Atp7b−/− animal models. The most commonly described dysfunctions in Wilson’s disease patients are hepatic steatosis and cirrhosis. Surprisingly little is known regarding glucose and lipid metabolism in these patients, and the limited available case reports disagree regarding glucose tolerance in Wilson’s disease patients (13, 14). Wilson’s disease is a rare autosomal recessive disorder (1:30,000 occurrence), and this lack of clear conclusion regarding glucose homeostasis in Wilson’s disease patients (2). Atp7b−/− mice provide a robust model for studying metabolism because environmental and genetic factors are more precisely controlled.

We measured multiple metabolic parameters in Atp7b−/− mice and WT littermate controls maintained on either normal chow or Western-type diets. Chow-fed Atp7b−/− mice exhibited modestly reduced adiposity and body weight by 14 wk of age. On WD, Atp7b−/− mice exhibited more pronounced reductions in body weight, adiposity, and hepatic steatosis in comparison with WT. The reduction in hepatic steatosis may be secondary to reduced obesity observed for WD-fed Atp7b−/− mice in comparison with WT littermate controls. Atp7b−/− mice ate less food and were more active, which may implicate a central component in the observed metabolic differences. Indeed, our microarray and real-time PCR data revealed a fourfold increase in hepatic Gdf15 expression for Chow–diet–fed Atp7b−/− mice in comparison with WT controls at 3 mo of age, prior to observed weight differences, and continuing through 6 mo of age. GDF15 has recently emerged as an inhibitor of food intake (21), suggesting that this anorectic hepatokine may contribute to decreased food intake observed in Atp7b−/− mice. Serum GDF15 levels were similarly elevated for Chow–fed Atp7b−/− mice of both age groups. Western diet feeding increased serum GDF15 levels in WT mice, with even higher levels in Atp7b−/− mice (SI Appendix, Fig. S10).

Our findings support previous reports of decreased hepatic and serum lipids in mixed-background Atp7b−/− mice (5, 6). However, significantly decreased hepatic and fasting plasma lipid levels relative to WT were evident only for Atp7b−/− mice when they were fed WD. This may reflect altered genetic susceptibility to lipid synthesis, oxidation, and accumulation among mouse strains since Atp7b−/− mice on WD did have decreased serum and hepatic cholesterol and triglyceride levels in comparison with WT mice. In previous studies, white adipose tissue (WAT) in mixed-background Atp7b−/− mice showed a correlation between copper levels and lipolysis in explant WAT (22), and copper levels were inversely correlated with steatosis in nonalcoholic fatty liver disease (NAFLD) patients (23, 24) and rodent NAFLD models (25, 26). While we did not observe an effect on fasting-plasma free fatty acids, it remains to be determined whether the decreased adiposity observed in Atp7b−/− mice on the C57BL/6 background is in part due to a primary alteration in adipocyte function or to a secondary effect of copper accumulation in the liver or elsewhere. Interestingly, hepatocyte-specific knockout of Atp7b (Atp7bΔHep) resulted in increased adiposity and weight gain despite limited hepatic inflammation, possibly due to alterations in cell signaling in nonparenchymal cells and to increased metallothionein expression (copper chelation) in Atp7bΔHep mice (27). Furthermore, Atp7bΔHep−/−, but not Atp7bΔHep−/− mice, have abnormal enterocyte morphology, accumulation of enteric lipid droplets, and disrupted chylomicron assembly (28), which may account for differences in metabolic phenotype between Atp7b−/− and Atp7bΔHep−/− mice.

Recent findings in an Atp7b−/− rat model (cross breed between the Long-Evans–Cinnamon rat and the Piebald Virol Glaxo rat, defective in pineal night-specific ATPase [PINA] and Atp7b [LPP rat]) demonstrated increased visceral fat, hepatic triglyceride content, liver weight, and macrosteatosis in response to a high-calorie diet (45% kcal from fat and 722 kcal/L fructose-supplemented drinking water), which correlated with increased hepatic mitochondrial damage (29). In contrast with Atp7b−/− mice, LPP rats did not have aberrations in visceral fat or other parameters of lipid metabolism on a normal diet (29). There are potential genetic and physiologic reasons underlying these differences. The PINA gene is
expressed from an intronic promoter within the Atp7b gene and is deleted in the LPP rat but not the Atp7b−/− mouse (30). Given the important role of circadian rhythm in metabolism, circadian disruptions arising from defective PINA activity may contribute to different metabolic outcomes between LPP rats and Atp7b−/− mice. Furthermore, LPP rats develop fulminant liver failure followed by death, such that untreated animals die between 90 and 120 d of age, whereas Atp7b−/− mice are longer-lived (31). The basis for this difference in disease progression is unclear since both animal models have similar levels of hepatic copper accumulation.

GTT, ITT, hyperinsulinemic euglycemic clamps, and skeletal muscle AMPK activation demonstrated increased glucose tolerance and insulin sensitivity in Atp7b−/− mice. However, marked hypoglycemia during ITTs, as well as PTT data, also supported a defective counterregulatory response. Gene expression data indicate marked down-regulation of gluconeogenic genes in livers of Atp7b−/− mice, and glycogen storage and glycogenesis may also be reduced in Atp7b−/− mice, suggesting that glucose production may be impaired in patients with Wilson’s disease and render them more susceptible to episodes of hypoglycemia when fasting, particularly under conditions of increased nonglucose-stimulated insulin secretion. Thus far, one published case study has reported hypoglycemia, which resolved with treatment, in a patient diagnosed with Wilson’s disease (32). Furthermore, cirrhosis is often observed in Wilson’s disease patients and is frequently associated with aberrant nutritional status. Patients with liver cirrhosis may present with hypocholesterolemia, impaired absorption of fat-soluble vitamins, glycogen storage disorders, impaired gluconeogenesis, and increased catabolism (33). Therefore, the improved glucose tolerance in Atp7b−/− mice may reflect progressive liver damage, rather than a component of normal/healthy metabolism, due to effects on glucose production. Our results suggest an impaired glucose counterregulatory response as a potential mechanism for hypoglycemic episodes in the context of Atp7b deficiency.

The metabolic aberrations that we observed in Atp7b−/− mice are consistent with impaired nuclear receptor activity. Expression of Ppara and of many of its targets decreased in Atp7b−/− vs. WT mice. Atp7b−/− mice had impaired expression of several FXR-regulated gluconeogenic target genes, in agreement with reduced FXR activity in this mouse model (7, 8). Analysis of transcription-factor–binding sites upstream of differentially regulated genes suggested increased AR activity. Classical ligand-dependent activation of AR has been shown to be protective against NAFLD and insulin resistance in male mice (34), whereas nonligand-dependent activation of AR via MAPK signaling has been shown to promote hepatocarcinogenesis (35). Furthermore, reduced gluconeogenic capacity and hepatic glycogen synthesis are in keeping with reduced glucocorticoid receptor (GR) and circulating glucocorticoid levels observed for Atp7b−/− mice (7). GR expression and activity have been reported to be directly controlled by FXR activity, influencing hepatic gluconeogenic responses in the fasted state in mice (36). Further chromatin immunoprecipitation sequencing (ChIP-seq) analysis in Atp7b−/− and control livers is necessary to

Fig. 4. Hepatic metabolic changes in Atp7b−/− mice. (A) Hepatic glycolytic/TCA cycle metabolites significantly changed (B) hepatic Pepck2 mRNA, (C) hepatic regulators of the pyruvate dehydrogenase complex, and (D) hepatic TCA cycle genes. (A) Student’s t test followed by false discovery rate (FDR) correction; *q < 0.25. n = 4 to 7 mice per group. (B–D) n = 5 to 11 mice per group. Student’s t test was used to determine differences between Atp7b−/− mice vs. WT controls; *P < 0.05 vs. WT.
expression. Future studies measuring TCA cycle flux are necessary to uncover therapeutic options for patients with Wilson disease. We observed increased hepatic AMPK activation in Atp7b−/− mice, which may play a larger role in mediating the cellular response to excess ROS production.

Increased hepatic AMPK activation may be responsible for reduced gluconeogenic and lipogenic gene expression. AMPK serves as a sensor of energy status, as well as cellular stress (such as ROS production) (37–40). Copper-induced production of ROS is well characterized in Wilson disease patients and animal models (2) and may provide a stimulus for AMPK activation in Atp7b−/− mice. Alternatively, AMPK is activated in response to UCP2-mediated depletion of cellular ATP (41, 42). Ucp2 has been identified as a transcriptional target of both FOXM1 (43) and E2F4 (44, 45), the transcription factors with the two most highly up-regulated binding sites identified in our study. FOXM1 expression has been reported to be up-regulated by GDF15, activated by oxidative stress, and to negatively regulate expression of the copper transporter Ctr1, suggesting that FoxM1 may play a larger role in mediating the cellular response to excess copper (46, 47).

Future studies will investigate the underlying mechanisms for AMPK activation and the impact on metabolism in Atp7b−/− mice. AMPK activation in Atp7b−/− mice may lead to an increased AMP/ATP ratio, which could stimulate the activity of AMPK, a key regulator of cellular energy homeostasis. AMPK activation in Atp7b−/− mice is likely a consequence of impaired hepatic nuclear receptor function. We observed decreased glucose and lactate concentrations, as well as increased AMPK activity, in Atp7b−/− mice. In addition, we observed increased hepatic AMPK activation in Atp7b−/− mice, which may play a larger role in mediating the cellular response to excess ROS.

Decreased gluconeogenesis, hepatic glucose, pyruvate, and lactate concentrations were accompanied by a significant increase in glycolytic intermediates, as well as unexpected increases in many TCA cycle intermediates despite decreased Ac-CoA. In support of decreased TCA cycle metabolic flux, we found increased Pdk4 mRNA expression. Further studies measuring TCA cycle flux are necessary to determine the mechanism for increased TCA cycle intermediates.

Here we describe metabolic changes in Atp7b−/− mice that are likely a consequence of impaired hepatic nuclear receptor function. We observed dramatic alterations in glucose homeostasis, metabolome, and AMPK activation in Atp7b−/− mice. Future studies to elucidate the mechanisms for decreased adiposity and altered whole-body glucose homeostasis have the potential to uncover therapeutic options for patients with Wilson’s disease, as well as for patients with metabolic disorders such as type 2 diabetes and fatty liver disease.
Microarray Analysis. RNA was harvested from male and female 3-mo-old Atbp7+/− mice and WT controls with TRIzol Reagent (Invitrogen), followed by RNeasy kit (Qiagen). Microarray processing using a GeneChip Mouse 430 2.0 (Affymetrix) was performed in the Genomic and RNA Profiling Group at BCM. Data are available at the Gene Expression Omnibus database under accession no. GSE125637 (52). Datasets were analyzed as previously described (31).

Serum Growth/Differentiation Factor 15 Measurement. Serum from ad-libitum-fed mice was collected and analyzed using the Mouse/Rat GDF-15 Quantikine ELISA Kit (R&D Systems) per manufacturer protocol.

Statistical Analysis. Statistical analysis was performed with GraphPad Prism software (v7.0). Data are presented as mean ± SEM, and P < 0.05 was considered statistically significant. Student’s t test was used to compare differences between two groups. For multiple-group comparison, two-way ANOVA tests followed by Sidak’s post hoc test were performed.

Acknowledgments. We thank Drs. Curtis Hughey and Svetlana Lutsenko for useful discussions and edits; Mr. Jordan Mat for technical assistance with the mouse diet study; Mr. Firoz Vohra and Dr. Marta Fiorotto, both of the CNRC MMRU Core; Dr. Michael Gruskas for mineral composition studies performed at the CNRC; and Dr. Milton Finegold and Dr. Michael Ittmann for advice on analysis of liver histology. This work was supported by National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) Grants K01DK111716-03 and P30 DK056338 (to C.R.W.K.); USDA-ARS Grant 3092-51000-060-035 and American Heart Association Grant 18CDA34110137 (to A.M.N.-A.); R. P. Doherty, Jr., Welch Chair in Science Grant Q-0022 and Cancer Prevention Research Institute of Texas (CPRIT) Grant RP150587-00 (to D.D.M.); CPRIT Proteomics and Metabolomics Core Facility RP170005 (to N.P. and C.C.); Mouse Metabolic and Phenotyping Core (MMPC) at Baylor College of Medicine and NIH Grants R01DK114582 and U54GM065348 (to P.S.). We acknowledge the joint participation of the Diana Helis Henry Medical Research Foundation through its direct engagement in the continuous active conduct of medical research in conjunction with BCM. The MMRU at the USDA/ARS CNRC, Baylor College of Medicine, is supported by funds from the USDA/ARS (https://www.bcm.edu/research/advanced-technology-core/labs/lablisting/mouse-metabolic-research-unit).